A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Interventions

DRUG: AMO959
RADIATION: AAA617
DRUG: Enzalutamide
DRUG: Abiraterone

Sponsor

Novartis Pharmaceuticals